3SBio Inc., a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1530), has reported its interim financial results for 2024. The company’s operating revenue for the period stood at RMB 4.389 billion (USD 614.6 million), reflecting a substantial year-on-year (YOY) increase of 16%. The adjusted EBITDA also showed a healthy YOY growth of 17%, amounting to RMB 1.664 billion (USD 233 million).
The biomedicine segment of 3SBio had a particularly strong performance. TPIAO, a recombinant thrombopoietin, achieved sales of RMB 2.476 billion during the first half of 2024, marking a significant YOY increase of 22.6%. It also received its third indication approval for treating persistent or chronic primary immune thrombocytopenia in children or adolescents. The company’s recombinant human erythropoietin (rhEPO) products, including the first-generation EPIAO and second-generation SEPO, reported combined sales of RMB 516 million, an 11.3% increase. Yisaipu, a biosimilar etanercept used for conditions like rheumatoid arthritis and psoriasis, saw sales growth of 9.5%, reaching RMB 329 million. Cipterbin, an anti-HER2 monoclonal antibody for HER2 positive metastatic breast cancer, demonstrated the most impressive growth with a 48.9% YOY increase, contributing RMB 162 million in sales.
The hair health product category also made a notable contribution to the company’s growth, with the minoxidil foam agent, which received marketing approval in January 2024, generating RMB 550 million in the first half of the year, up 10.0% YOY.
3SBio’s robust pipeline comprises 28 programs in development across various therapeutic areas, including 12 in hematology and oncology, 10 in autoimmunology and ophthalmology, 4 in nephrology, 1 in dermatology, and 1 in metabolism. Of these, 12 novel drugs have reached Phase III or are at the New Drug Application (NDA) filing stages, while 2 generic products are in the Abbreviated New Drug Application (ANDA) filing stages.- Flcube.com
